Clinical Trial Update: A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. [Phase 1]

View source ↗

Summary

Chiome Bioscience is conducting a Phase 1, first-in-human trial of CBA-1535, a 5T4/CD3 bispecific T cell engager, in patients with advanced solid tumors. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• CBA-1535 (CBA-1535)

Snippet

Sponsor: Chiome Bioscience Inc. | Conditions: Solid Tumors, Refractory Cancer | Phase 1 | Status: RECRUITING